$955 Million is the total value of Rhenman & Partners Asset Management AB's 90 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 11.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNH | Sell | UNITED HEALTH GROUP INC | $30,422,000 | +5.8% | 54,800 | -2.1% | 3.19% | -2.5% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $29,961,000 | +10.9% | 695,000 | -4.1% | 3.14% | +2.2% |
| CI | Sell | CIGNA CORP NEW | $24,230,000 | -17.2% | 75,000 | -32.4% | 2.54% | -23.7% |
| ABBV | Sell | ABBVIE INC | $21,905,000 | -24.7% | 149,626 | -21.2% | 2.29% | -30.6% |
| ANTM | Sell | ELEVANCE HEALTH INC | $21,871,000 | -20.5% | 40,000 | -29.8% | 2.29% | -26.7% |
| MRK | Sell | MERCK & CO. INC | $21,758,000 | -9.9% | 215,000 | -18.9% | 2.28% | -17.0% |
| CVS | Sell | CVS HEALTH CORP | $21,308,000 | -20.7% | 225,000 | -22.4% | 2.23% | -26.9% |
| MCK | Sell | MCKESSON CORP | $19,469,000 | -5.3% | 50,000 | -20.6% | 2.04% | -12.7% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $18,908,000 | -24.3% | 131,500 | -17.8% | 1.98% | -30.2% |
| PFE | Sell | PFIZER INC | $16,293,000 | -42.5% | 350,000 | -35.2% | 1.71% | -47.0% |
| AXNX | Sell | AXONICS INC | $15,359,000 | +12.9% | 210,000 | -12.5% | 1.61% | +4.1% |
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $12,324,000 | -2.8% | 237,000 | -8.8% | 1.29% | -10.5% |
| ISRG | Sell | INTUITIVE SURGICAL INC | $12,324,000 | -12.3% | 50,000 | -28.6% | 1.29% | -19.2% |
| ABT | Sell | ABBOTT LABS | $11,576,000 | -37.3% | 117,000 | -31.2% | 1.21% | -42.3% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $9,555,000 | +3.2% | 83,000 | -12.6% | 1.00% | -4.8% |
| PRVA | Sell | PRIVIA HEALTH GROUP INC | $9,274,000 | +6.2% | 277,000 | -7.7% | 0.97% | -2.2% |
| CYTK | Sell | CYTOKINETICS INC | $9,169,000 | +1.5% | 210,000 | -8.7% | 0.96% | -6.5% |
| RVNC | Sell | REVANCE THERAPEUTICS INC | $8,656,000 | +39.2% | 388,000 | -13.8% | 0.91% | +28.1% |
| DVAX | Sell | DYNAVAX TECHNOLOGIES CORP | $8,399,000 | -16.6% | 733,519 | -8.3% | 0.88% | -23.2% |
| XNCR | Sell | XENCOR INC | $8,234,000 | +0.3% | 294,076 | -2.0% | 0.86% | -7.6% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $8,102,000 | -68.8% | 130,000 | -60.0% | 0.85% | -71.2% |
| SILK | Sell | SILK RD MED INC | $6,832,000 | +7.3% | 155,000 | -11.4% | 0.72% | -1.2% |
| IMGN | Sell | IMMUNOGEN INC | $6,534,000 | +21.0% | 1,100,000 | -8.3% | 0.68% | +11.4% |
| SWAV | Sell | SHOCKWAVE MEDICAL INC | $5,863,000 | -56.8% | 20,000 | -71.8% | 0.61% | -60.2% |
| VEEV | Sell | VEEVA SYS INC | $5,794,000 | -23.0% | 34,500 | -9.2% | 0.61% | -29.0% |
| ITCI | Sell | INTRA-CELLULAR THERAPIES INC | $5,709,000 | -28.6% | 125,000 | -10.7% | 0.60% | -34.1% |
| SGEN | Sell | SEAGEN INC | $5,214,000 | -34.8% | 41,000 | -9.3% | 0.55% | -39.9% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $4,763,000 | -18.6% | 510,000 | -3.8% | 0.50% | -25.0% |
| GKOS | Sell | GLAUKOS CORP | $4,766,000 | +16.6% | 85,000 | -5.5% | 0.50% | +7.5% |
| ALLO | Sell | ALLOGENE THERAPEUTICS INC | $3,502,000 | -12.2% | 340,000 | -2.9% | 0.37% | -19.0% |
| GH | Sell | GUARDANT HEALTH INC | $3,218,000 | -16.0% | 65,000 | -31.6% | 0.34% | -22.5% |
| NVCR | Sell | NOVOCURE LTD | $2,473,000 | -40.7% | 35,000 | -41.7% | 0.26% | -45.4% |
| ONEM | Exit | 1LIFE HEALTHCARE INC | $0 | – | -375,250 | -100.0% | -0.33% | – |
| MYOV | Exit | MYOVANT SCIENCES LTD | $0 | – | -310,000 | -100.0% | -0.44% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -562,350 | -100.0% | -0.48% | – |
| ALGN | Exit | ALIGN TECHNOLOGY INC | $0 | – | -18,000 | -100.0% | -0.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.